Langenbeck's Archives of Surgery

, Volume 394, Issue 2, pp 221–226 | Cite as

Procalcitonin (PCT)-guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a prospective randomized study

  • S. Schroeder
  • M. Hochreiter
  • T. Koehler
  • A.-M. Schweiger
  • B. Bein
  • F. S. Keck
  • T. von Spiegel
Controlled Prospective Clinical Trials

Abstract

Background

Adequate indication and duration of administration are central issues of modern antibiotic treatment in intensive care medicine. The biochemical variable procalcitonin (PCT) is known to indicate systemically relevant bacterial infections with high accuracy. In the present study, we aimed to investigate the clinical usefulness of PCT for guiding antibiotic treatment in surgical intensive care patients with severe sepsis.

Patients and methods

Patients were randomly assigned to a PCT-guided or a control group requiring antibiotic treatment. All patients received a calculated antibiotic regimen according to the presumed microbiological spectrum. In the PCT-guided group, antibiotic treatment was discontinued if clinical signs of infection improved and the PCT value was either <1 ng/ml or decreased to <35% of the initial concentration within three consecutive days. In the control group, antibiotic treatment was directed by empirical rules.

Results

The PCT-guided group (n = 14 patients) and the control group (n = 13 patients) did not differ in terms of biological variables, underlying diseases, and overall disease severity. PCT guidance led to a significant reduction of antibiotic treatment from 6.6 ± 1.1 days (mean ± SD) compared with 8.3 ± 0.7 days in control patients (p < 0.001) along with a reduction of antibiotic treatment costs of 17.8% (p < 0.01) without any adverse effects on outcome.

Conclusions

Monitoring of PCT is a helpful tool for guiding antibiotic treatment in surgical intensive care patients with severe sepsis. This may contribute to an optimized antibiotic regimen with beneficial effects on microbial resistances and costs in intensive care medicine.

Keywords

Procalcitonin Antibiotic treatment Surgical intensive care unit Severe sepsis Randomized clinical study 

References

  1. 1.
    ACCP/SCCM Consensus Conference Committee (1992) Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874CrossRefGoogle Scholar
  2. 2.
    Brunkhorst FM, Al-Nawas B, Krummenauer F, Forycki ZF, Shah PM (2002) Procalcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect 8:93–100PubMedCrossRefGoogle Scholar
  3. 3.
    Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, Clementi E, Gonzalez J, Jusserand D, Asfar P, Perrin D, Fieux F, Aubas S, PneumA Trial Group (2003) Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 290:2588–2598PubMedCrossRefGoogle Scholar
  4. 4.
    Christ-Crain M, Müller B (2005) Procalcitonin in bacterial infections—hype, hope, more or less? Swiss Medical Weekly 135:451–460PubMedGoogle Scholar
  5. 5.
    Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, Zimmerli W, Harbarth S, Tamm M, Müller B (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. Am J Respir Crit Care Med 174:84–93PubMedCrossRefGoogle Scholar
  6. 6.
    Engel C, Brunkhorst FM, Bone HG, Brunkhorst R, Gerlach H, Grond S, Gruendling M, Huhle G, Jaschinski U, John S, Mayer K, Oppert M, Olthoff D, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Bogatsch H, Hartog C, Loeffler M, Reinhart K (2007) Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 33:606–618PubMedCrossRefGoogle Scholar
  7. 7.
    Harbarth S (2007) Antibiotikatherapie—Einfluss des Antibiotikaverbrauchs auf Resistenzbildung und–selektion. Anästhesiol Intensivmed Schmerzther 2:130–135CrossRefGoogle Scholar
  8. 8.
    Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, Vadas L, Pugin J, Geneva Sepsis Network (2001) Diagnostic value of procalcitonin, interleukin 6 and interleukin 8 in critically ill patients admitted with suspected sepsis. Am J Respirat Crit Care Med 164:396–402Google Scholar
  9. 9.
    Hedlund J, Hansson LO (2000) Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 28:68–73PubMedCrossRefGoogle Scholar
  10. 10.
    Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH (2002) Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122:262–268PubMedCrossRefGoogle Scholar
  11. 11.
    Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Cheang M (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:1589–1596PubMedCrossRefGoogle Scholar
  12. 12.
    Le Gall JR, Lemeshow S, Saulnier F (1993) A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957–2963PubMedCrossRefGoogle Scholar
  13. 13.
    Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, Caladra T, Glauser MP, Tauber MG, Pittet D (2004) Fungal infection network of Switzerland. Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000. Clin Infect Dis 38:311–320PubMedCrossRefGoogle Scholar
  14. 14.
    Meisner M, Tschaikowsky K, Palmaers T, Schmidt J (1999) Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Critical Care 3:45–50PubMedCrossRefGoogle Scholar
  15. 15.
    Meyer E, Jonas D, Schwab F, Gastmeier P, Rüden H, Daschner FD (2004) SARI: surveillance of antibiotic use and bacterial resistance in German intensive care units. Correlation between antibiotic use and the emergence of resistance. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 47:345–351PubMedCrossRefGoogle Scholar
  16. 16.
    Micek S, Heuring TJ, Hollands JM, Shah RA, Kollef MH (2006) Optimizing antibiotic treatment for ventilator-associated pneumonia. Pharmacotherapy 26:204–213PubMedCrossRefGoogle Scholar
  17. 17.
    Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J (2008) Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177:498–505PubMedCrossRefGoogle Scholar
  18. 18.
    Oberhoffer M, Vogelsang H, Russwurm S, Hartung T, Reinhart K (1999) Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med 37:363–368PubMedCrossRefGoogle Scholar
  19. 19.
    Rau BM, Frigerio I, Büchler MW, Wegscheider K, Bassi C, Puolakkainen PA, Beger HG, Schilling MK (2007) Evaluation of procalcitonin for predicting septic multiorgan failure and overall prognosis in secondary peritonitis: a prospective, international multicenter study. Arch Surg 142:134–142PubMedCrossRefGoogle Scholar
  20. 20.
    Rau B, Krüger CM, Schilling MK (2004) Procalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis. Langenbecks Arch Surg 389:134–144PubMedCrossRefGoogle Scholar
  21. 21.
    Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL (2000) Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 162:505–511PubMedGoogle Scholar
  22. 22.
    Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710PubMedCrossRefGoogle Scholar
  23. 23.
    Wahl HG, Herzum I, Renze H (2003) Sepsis und Sepsismarker—update. J Lab Med 27:431–439CrossRefGoogle Scholar
  24. 24.
    Welte T (2004) Antibiotikatherapie bei Sepsis. Dtsch Med Wochenschr 129:2609–2613PubMedCrossRefGoogle Scholar
  25. 25.
    Welte T (2006) Die nosokomiale Pneumonie. Intensivmed 43:301–309CrossRefGoogle Scholar
  26. 26.
    Yu V, Singh N (2004) Excessive antimicrobial usage cause measurable harm to patients with suspected ventilator-associated pneumonia. Intensive Care Med 30:735–738PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • S. Schroeder
    • 1
    • 3
  • M. Hochreiter
    • 1
  • T. Koehler
    • 1
  • A.-M. Schweiger
    • 1
  • B. Bein
    • 2
  • F. S. Keck
    • 1
  • T. von Spiegel
    • 1
  1. 1.Interdisciplinary Intensive Care Unit, Department of Anaesthesiology and Intensive Care MedicineHeideGermany
  2. 2.Department of Anaesthesiology and Intensive Care MedicineUniversity of KielKielGermany
  3. 3.Department of Anaesthesiology and Intensive Care MedicineHeideGermany

Personalised recommendations